{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:05:50Z","timestamp":1790175950202,"version":"4.1.0"},"reference-count":92,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2020,4,2]]},"DOI":"10.1080\/14728214.2020.1773792","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T17:23:17Z","timestamp":1590254597000},"page":"189-200","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":16,"title":["Emerging 5-HT receptor antagonists for the treatment of Schizophrenia"],"prefix":"10.1080","volume":"25","author":[{"given":"Mackenzie T.","family":"Jones","sequence":"first","affiliation":[{"name":"Miller School of Medicine, University of Miami, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin T.","family":"Strassnig","sequence":"additional","affiliation":[{"name":"Miller School of Medicine, University of Miami, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip D.","family":"Harvey","sequence":"additional","affiliation":[{"name":"Miller School of Medicine, University of Miami, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60692-4"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sby058"},{"key":"cit0003","volume-title":"Schizophrenia","author":"National Institute of Mental Health","year":"2009"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2004.09.007"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a007078"},{"key":"cit0006","unstructured":"Rice DP, Miller LS The economic burden of schizophrenia: conceptual and methodological issues, and cost estimates. Handbook of mental health economics and health policy, Vol. 1: schizophrenia. Handbook of mental health economics and health policy. Oxford, England: John Wiley & Sons; 1996. p. 321\u2013334."},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.15081035"},{"key":"cit0008","volume-title":"Dementia Praecox and Paraphrenia","author":"Kraepelin E.","year":"1919"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1177\/0957154X14554369"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.07.014"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04250yel"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2014.03.008"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2012.05.009"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbj053"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.4103\/ipj.ipj_30_15"},{"key":"cit0016","volume-title":"Dementia praecox and paraphrenia","author":"Kraepelin E","year":"1971"},{"key":"cit0017","volume-title":"Dementia praecox or the group of schizophrenias","author":"Bleuler E","year":"1950"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.scog.2014.02.001"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.3.418"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.05.022"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2015.03.033"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0552-9"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.10.1079"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbp116"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.06.023"},{"issue":"4","key":"cit0026","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1176\/ajp.156.4.637","volume":"156","author":"Amador XF","year":"1999","journal-title":"Am J Psychiatry"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1037\/0894-4105.11.3.437"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1037\/0894-4105.19.6.778"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2018.06.018"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2016.01.006"},{"key":"cit0031","volume":"55","author":"Lee MA","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.154.6.799"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.6.985"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2006.08.021"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04634"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.2.176"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.64.6.633"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852913000904"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1192\/S0007125000291496"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.151.6.825"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1159\/000285058"},{"issue":"11","key":"cit0043","first-page":"30","volume":"14","author":"Khan A","year":"2017","journal-title":"Innov Clin Neurosci"},{"key":"cit0044","first-page":"18","volume":"14","author":"Harvey PD","year":"2017","journal-title":"Innov Clin Neurosci"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2013.01.015"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbq059"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/19.3.627"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2011.06.030"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2017.11.031"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbz141"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199812010-00024"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3007-12.2013"},{"key":"cit0053","volume":"2018","author":"Sommer IEC","year":"2018","journal-title":"BMJ Case Rep"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2010.46.3.1437247"},{"key":"cit0055","unstructured":"Forecasts for HMR\u2019s M100907 antipsychotic putney [Internet]. London: The Pharma Letter; 1998 [cited 2020 Mar 20]. Available from: https:\/\/www.thepharmaletter.com\/article\/forecasts-for-hmr-s-m100907-antipsychotic"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2019.02.024"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62106-6"},{"key":"cit0058","unstructured":"ACADIA pharmaceuticals presents positive top-line results from pivotal phase 3 harmony trial of pimavanserin in patients with dementia-related psychosis at 12th clinical trials on Alzheimer\u2019s disease (CTAD) meeting [Internet]. San Diego, CA: Business Wire; December 4, 2019 [cited 2020 Mar 20]. Available from: https:\/\/www.businesswire.com\/news\/home\/20191204005956\/en\/"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.07.029"},{"key":"cit0060","unstructured":"ACADIA pharmaceuticals announces top-line results from phase 3 enhance trial of pimavanserin as adjunctive treatment for patients with schizophrenia [Internet]. San Diego, CA: Business Wire; July 22, 2019 [cited 2020 Mar 20]. Available from: https:\/\/www.businesswire.com\/news\/home\/20190722005666\/en\/."},{"key":"cit0061","unstructured":"ACADIA pharmaceuticals announces positive top-line results from advance trial of pimavanserin as treatment for negative symptoms of schizophrenia [Internet]. San Diego, CA: Business Wire; November 25, 2019 [cited 2020 Mar 20]. Available from: https:\/\/www.businesswire.com\/news\/home\/20191125005784\/en\/ *Trial of pimavanserin as adjunctive treatment in patients with predominantly negative symptoms showing promise for the treatment of negative symptoms."},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.2174\/138920112800784880"},{"key":"cit0063","unstructured":"Moore TJ, Cohen MR, Fuberg CD, et al. Safety signals for two novel drugs [Internet]. QuarterWatch. 2017 [cited 2020 Mar 20] Available from: https:\/\/ismp.org\/sites\/default\/files\/attachments\/2018-01\/2017Q1_0.pdf"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006396"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.17010122"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.3390\/ph4060880"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1002\/syn.21717"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.2174\/138161212799436458"},{"issue":"3","key":"cit0069","first-page":"900","volume":"292","author":"Vilner BJ","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2005.05.009"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1038\/npp.1994.5"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.180638"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17m11753"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2019.08.029"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(01)00249-4"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.06.034"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.18030349"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3704-1"},{"key":"cit0079","unstructured":"FDA approves Intra-Cellular Therapies\u2019 novel antipsychotic CAPLYTA [Internet]. December 23, 2019 [cited 2020 May 1]. Available from: https:\/\/ir.intracellulartherapies.com\/news-releases\/news-release-details\/fda-approves-intra-cellular-therapies-novel-antipsychotic"},{"key":"cit0080","unstructured":"Intra-Cellular Therapies I. Caplyta (lumateperone) capsules, for oral use: US prescribing information. 2019."},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2015.08.026"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.7.681"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.4379"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2015.10.002"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1080\/08039480801984008"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbr046"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.12.012"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.05.004"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1016\/j.scog.2019.100152"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2010.5"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2014.192"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2020.1773792","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T18:32:47Z","timestamp":1666636367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2020.1773792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,2]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4,2]]}},"alternative-id":["10.1080\/14728214.2020.1773792"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2020.1773792","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}